for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bausch Health Companies Inc

BHC.TO

Latest Trade

21.98CAD

Change

-0.74(-3.26%)

Volume

483,575

Today's Range

21.55

 - 

22.18

52 Week Range

16.30

 - 

42.15

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
22.72
Open
22.15
Volume
483,575
3M AVG Volume
13.26
Today's High
22.18
Today's Low
21.55
52 Week High
42.15
52 Week Low
16.30
Shares Out (MIL)
354.99
Market Cap (MIL)
8,089.95
Forward P/E
4.73
Dividend (Yield %)
--

Next Event

Q3 2020 Bausch Health Companies Inc Earnings Release

Latest Developments

More

Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics

Bausch Health Announces Intention To Spin Off Eye Health Business Into Independent Publicly Traded Company

Bausch Health Companies Posts Quarterly Loss Per Share $0.92

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bausch Health Companies Inc

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Industry

Biotechnology & Drugs

Contact Info

2150 Saint-Elzear Blvd W

LAVAL, QC

H7L 4A8

Canada

+1.514.7446792

https://www.bauschhealth.com

Executive Leadership

Joseph C. Papa

Chairman of the Board, Chief Executive Officer

Paul S. Herendeen

Chief Financial Officer, Executive Vice President

Thomas J. Appio

President & Co-Head Bausch + Lomb/International

Joseph F. Gordon

President & Co-Head Bausch + Lomb/International

William Douglas Humphries

President of Ortho-Dermatologics

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

8.7K

2018

8.4K

2019

8.6K

2020(E)

7.8K
EPS (USD)

2017

3.830

2018

3.970

2019

4.360

2020(E)

3.577
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.76
Price To Book (MRQ)
12.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5,138.82
LT Debt To Equity (MRQ)
5,138.61
Return on Investment (TTM)
-7.40
Return on Equity (TTM)
-6.41

Latest News

Latest News

CANADA STOCKS-TSX scales 5-month high on Bausch Health, oil surge

Canada's main stock index scaled a five-month high on Thursday as a surge in shares of drugmaker Bausch Health and higher oil prices outweighed disappointment over earnings, including Bombardier's surprise quarterly loss.

UPDATE 2-Bausch Health to spin off eye care business, shares soar

Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin off its eye care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.

Bausch Health to spin-off eye care business

Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin-off its eye care unit Bausch + Lomb into a separate publicly listed company.

Bausch Health, three former executives agree to penalties to resolve U.S. SEC charges

Bausch Health Companies Inc <BHC.TO> has agreed to pay $45 million, and three of former top executives also agreed to penalties, to settle charges of improper revenue recognition and misleading disclosures in U.S. regulatory filings, the U.S. Securities and Exchange Commission...

Bausch Health agrees to pay $45 mln to settle U.S. charges of misleading disclosures

Canada-based Bausch Health Companies Inc has agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures in Securities and Exchange Commission filings and earnings presentations, the SEC said on Friday.

BRIEF-Health Canada Issues Notice Of Compliance For Bausch Health's DUOBRII

* HEALTH CANADA ISSUES NOTICE OF COMPLIANCE FOR BAUSCH HEALTH'S DUOBRII™

BRIEF-FDA Provides 510(K) Clearance For Bausch + Lomb Infuse™ Contact Lenses

* FDA PROVIDES 510(K) CLEARANCE FOR BAUSCH + LOMB INFUSE™ DAILY DISPOSABLE SILICONE HYDROGEL (SIHY DAILY) CONTACT LENSES

BRIEF-Bausch Health Reports Launch Of Private Offering Of Senior Notes

* BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES AND CONDITIONAL REDEMPTION OF EXISTING SENIOR SECURED NOTES

BRIEF-Bausch Health And Alfasigma Announce Resolution Of Xifaxan Intellectual Property Litigation

* BAUSCH HEALTH AND ALFASIGMA ANNOUNCE RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION

BRIEF-FDA Approves Ortho Dermatologics' Labeling For Jublia (Efinaconazole) Topical Solution

* FDA APPROVES ORTHO DERMATOLOGICS' LABELING FOR JUBLIA® (EFINACONAZOLE) TOPICAL SOLUTION, 10%, IN PATIENTS AS YOUNG AS SIX YEARS OLD

BRIEF-Clearside Biomedical Revises NDA Resubmission Timeline And XIPERE Commercial Deal With Bausch Health

* CLEARSIDE BIOMEDICAL REVISES NDA RESUBMISSION TIMELINE AND XIPERE™ COMMERCIAL PARTNERSHIP WITH BAUSCH HEALTH

BRIEF-Bausch Health Initiates Virazole Clinical Study In Patients With COVID-19

* BAUSCH HEALTH INITIATES VIRAZOLE (RIBAVIRIN FOR INHALATION SOLUTION, USP) CLINICAL STUDY IN PATIENTS WITH COVID-19

BRIEF-Glenview Capital Management LLC Reports 5.10% Passive Stake In Bausch Health Companies

* GLENVIEW CAPITAL MANAGEMENT LLC REPORTS 5.10% PASSIVE STAKE IN BAUSCH HEALTH COMPANIES INC AS OF APRIL 8 - SEC FILING Source text : (https://bit.ly/3b80eyg) Further company coverage:

BRIEF-Bausch Health - Favorable Topline Results From Study Evaluating Rifaximin Ssd Ir To Treat Overt Hepatic Encephalopathy

* BAUSCH HEALTH ANNOUNCES FAVORABLE TOPLINE RESULTS FROM STUDY EVALUATING INVESTIGATIVE FORMULATION OF RIFAXIMIN SSD IR TO TREAT OVERT HEPATIC ENCEPHALOPATHY

BRIEF-Cipher Pharmaceuticals Reports Q4 Total Revenue Of $5.9 Mln

* CIPHER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Bausch Health - Have Not Experienced Disruption In Supply Chain That Would Have Material Impact On Results Due To Covid-19

* BAUSCH HEALTH COMPANIES - HAVE NOT EXPERIENCED ANY DISRUPTION IN SUPPLY CHAIN THAT WOULD HAVE MATERIAL IMPACT ON RESULTS DUE TO COVID-19

BRIEF-Bausch Health Reports CEO Joseph C. Papa's 2019 Total Compensation Was $17.1 Mln

* BAUSCH HEALTH COMPANIES SAYS CEO JOSEPH C. PAPA'S FY 2019 TOTAL COMPENSATION WAS $17.1 MILLION VERSUS $14.7 MILLION IN 2018 - SEC FILING

BRIEF-Bausch Health To Reduce Debt By Approximately $100 Mln

* BAUSCH HEALTH TO REDUCE DEBT BY APPROXIMATELY $100 MILLION USING CASH GENERATED FROM OPERATIONS

BRIEF-Bausch Health To Reduce Debt By Approximately $100 Mln

* BAUSCH HEALTH TO REDUCE DEBT BY APPROXIMATELY $100 MILLION USING CASH GENERATED FROM OPERATIONS

BRIEF-Bausch Health Says Intends To Have Bausch Health Americas Issue $3.25 Billion Of Secured Debt Securities

* BAUSCH HEALTH ANNOUNCES IT IS SEEKING A REFINANCING AMENDMENT TO ITS EXISTING CREDIT AGREEMENT AND CONDITIONAL REDEMPTION OF EXISTING SENIOR SECURED NOTES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up